IDiyas

For the Inventor, By the Inventor

Pacifica, CA, United States of America

Joel McIntosh

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 7.7

ph-index = 7

Forward Citations = 143(Granted Patents)


Location History:

  • Pacifica, CA (US) (2010 - 2020)
  • San Francisco, CA (US) (2022 - 2024)

Company Filing History:

goldMedal7 out of 322 
 
Roche Palo Alto LLC
 patents
silverMedal3 out of 1,970 
 
Amgen Inc.
 patents
bronzeMedal2 out of 15,458 
 
University of California
 patents
4. 2 out of 14 
 
Nurix Therapeutics, Inc.
 patents

Years Active: 2010-2024

Loading Chart...
Loading Chart...
14 patents (USPTO):
1. 11866442 - Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway (2024-01-09),
2. 11479556 - Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway (2022-10-25),
3. 10836720 - Inhibitors of integrin alpha 5 beta 1 and methods of use (2020-11-17),
4. 10214522 - Anti-alphavbeta1 integrin inhibitors and methods of use (2019-02-26),
5. 9593129 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2017-03-14),
6. 9376425 - Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer (2016-06-28),
7. 9296736 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2016-03-29),
8. 8822457 - Inhibitors of bruton's tyrosine kinase (2014-09-02),
9. 8618098 - Inhibitors of bruton's tyrosine kinase (2013-12-31),
10. 8124604 - Inhibitors of bruton's tyrosine kinase (2012-02-28),
11. 7906509 - Inhibitors of bruton's tyrosine kinase (2011-03-15),
12. 7902194 - Inhibitors of bruton's tyrosine kinase (2011-03-08),
13. 7683064 - Inhibitors of Bruton's tyrosine kinase (2010-03-23),
14. 7645764 - Kinase inhibitors and methods for using the same (2010-01-12),

Of course! Here's the article about inventor Joel McIntosh:

Title: Unveiling the Inventive Mind of Joel McIntosh from Pacifica, CA

Introduction:

In the heart of Pacifica, CA, resides a prolific inventor named Joel McIntosh, whose innovative spirit has led to the creation of 14 patented inventions. Among these inventions, his latest breakthroughs revolve around bifunctional compounds designed to degrade BTK via the ubiquitin proteolytic pathway, offering new possibilities in the realm of pharmaceutical treatments.

Latest Patents:

Joel McIntosh's recent patents showcase his expertise in developing bifunctional compounds tailored for degrading BTK through the ubiquitin proteolytic pathway. These compounds not only demonstrate efficacy in protein degradation but also pave the way for novel pharmaceutical compositions that hold promise in treating various diseases, conditions, and disorders.

Career Highlights:

Currently, Joel McIntosh is a vital member of the pioneering team at Roche Palo Alto LLC, where his innovative contributions drive advancements in the pharmaceutical industry. His dedication to pushing the boundaries of science and medicine has solidified his reputation as a trusted inventor at the forefront of cutting-edge research.

Collaborations:

In his collaborative endeavors, Joel McIntosh has been privileged to work alongside esteemed colleagues such as Rama K Kondru and Yan Lou. Together, they harness their collective expertise to fuel innovation and bring revolutionary ideas to life, enriching the landscape of scientific discovery.

Conclusion:

Joel McIntosh's remarkable journey as an inventor underscores his unwavering commitment to driving progress and excellence in the field of pharmaceutical innovation. With a remarkable portfolio of patents and a steadfast dedication to groundbreaking research, he continues to shape the future of medicine and inspire the next generation of inventors.

I hope you find this information about Joel McIntosh insightful and engaging! If you have any more requests or need further assistance, feel free to ask.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…